When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
GT Biopharma, Inc.’s (GTBP) stock has more than quintupled since it began providing data from a Phase 1 trial evaluating its only clinical asset (GTB-3550) in the treatment of AML.
Bone marrow blast reductions were observed in three of five patients in the higher dose cohorts with no dose-limiting toxicity observed.
With a potential off-the-shelf (i.e. cost-effective) therapy for rescuing patients’ own natural killer cells without removing them, GT merited a deeper dive.
A full investment analysis follows in the paragraphs below.